Treace (TMCI) Q4 2025 earnings review
The Pivot to MIS Kits Crushes Top-Line Growth
Treace's evolution from a single-product Lapiplasty company to a 'comprehensive bunion solutions' provider has triggered a severe top-line contraction. Fourth-quarter revenue reversed to a 9% decline as surgeons actively shifted toward the company's newly launched, lower-priced minimally invasive (MIS) bunion kits. While management effectively controlled cash burn—cutting it by 46% in 2025—the growth narrative is broken. Initial 2026 guidance projects further revenue contraction of up to 6%, proving the ASP (Average Selling Price) headwind from the MIS transition will outpace any volume gains for at least another year.
🐂 Bull Case
Management successfully throttled back expenses, cutting FY25 cash usage by 46% to $27.3M and beating their own Adjusted EBITDA guidance significantly. They guide for another 50% cash burn reduction in 2026.
The company added 202 net new active surgeons in FY25, a 6% increase, reaching 3,337. The new product portfolio is successfully driving unit volume and attracting users, maintaining a 33% penetration of the US market.
🐻 Bear Case
The shift away from the premium Lapiplasty system to lower-priced MIS kits caused a 9% drop in Q4 revenue. The volume gains are mathematically failing to offset the severe ASP degradation.
With 2026 revenue guided to a 0% to -6% contraction, the long-term double-digit growth story is dead. Management hopes to 'restore topline growth in the back half of the year,' implying a brutal first half of 2026.
⚖️ Verdict: 🔴
Bearish. The company is successfully selling more units to more surgeons, but making less money doing it. Until volume growth mathematically overwhelms the ASP degradation, the stock lacks a top-line catalyst.
Key Themes
Severe Revenue Cannibalization from Product Mix
The most critical takeaway is the violent negative mix shift. Management explicitly blamed the 9% Q4 revenue drop on a 'shift in product sales toward lower priced bunion kits.' Throughout 2025, Treace aggressively rolled out its Nanoplasty and Percuplasty systems to capture the 70% of the market that prefers MIS osteotomies. However, the data directly contradicts the company's prior positive narrative that these products would be purely additive. Instead, the lower ASPs are aggressively cannibalizing overall revenue. The 2026 guidance implies this structural ASP compression will persist.
Aggressive Cash Preservation
In the face of collapsing top-line growth, management is pulling the correct levers on the balance sheet. Cash usage reversed sharply, falling 46% to $27.3M in FY25. For 2026, the company expects an accelerating ~50% reduction in cash burn, which implies ~$13.6M. With $48.4M in cash and marketable securities and a new $115M credit facility, this discipline provides the necessary runway without immediate equity dilution risk.
Profitability Metrics Show Resilience Amid ASP Pressure
Despite the $6.2M YoY drop in Q4 revenue, gross margins remained remarkably stable at 80.6% (vs 80.7% in 24Q4). Total operating expenses were held basically flat at $56.3M (+1% YoY). This confirms that COGS are scaling down proportionally with the lower-priced kits, and management has completely halted the bloated SG&A spending that characterized 2023 and early 2024.
Macroeconomic Deferrals of Elective Procedures
Beyond the product mix shift, the company continues to battle a sluggish macro environment for elective surgeries. Management previously highlighted soft consumer sentiment and procedure deferrals as patients delay out-of-pocket medical expenses. The prolonged pressure from these macro factors heavily contributes to the stagnant 2026 top-line forecast.
Technology Innovation: Shifting to 'Comprehensive' Solutions
The entire corporate pivot relies on continuous product launches. The rollout of Nanoplasty and Percuplasty MIS systems was designed to capture a wider audience. Going into 2026, the company is betting heavily on its expanded bunion portfolio and upcoming product launches (such as the anticipated Lapiplasty Lightning platform) to restore growth in the second half of the year.
Other KPIs
Accelerating improvement. The loss shrank by 64% from $11.0M in FY24. This was a massive beat compared to the company's own Q3 guidance, which projected a loss of $6.5M to $7.5M. The Q4 standalone EBITDA of $6.2M proves the model can generate positive underlying earnings during seasonally strong volume quarters.
Stable. Increased by 6% (202 net new surgeons) over 2024. The company now penetrates roughly 33% of the estimated 10,000 U.S. bunion surgeons. The volume thesis is working; the monetization thesis is currently failing.
Decelerating profitability on a GAAP basis. The net loss widened slightly from $(55.7)M in 2024. Q4 alone saw a net loss of $(9.4)M, significantly worse than the $(0.5)M in 24Q4, driven heavily by a $2.7M debt extinguishment loss and shrinking gross profit dollars.
Guidance
Reversing. Represents a -6% to 0% decline from FY25's $212.7M. This disastrous outlook confirms the Q4 mix-shift headwind is structural. Management expects new product volume to eventually restore growth in the 'back half of the year', but the full-year number implies a very weak H1 2026.
Decelerating. After printing an impressive $3.9M loss in FY25, guiding for a slightly wider loss in FY26 reflects the loss of operating leverage from shrinking top-line revenue, despite extreme cost containment efforts.
Accelerating. Implies cash usage of roughly $13.6M for FY26. Management is prioritizing survival and balance sheet protection over growth investments as they navigate the product transition.
Key Questions
ASP vs Volume Crossover
Given the 2026 guidance for revenue contraction, what is the blended ASP degradation you are modeling, and in what quarter do you expect unit volume growth to mathematically cross over the lower price point?
Margin Resilience on Lower Pricing
Gross margins held at 80.6% in Q4 despite the mix shift to lower-priced kits. Are the unit manufacturing costs on the MIS kits significantly lower, or are there price offsets sustaining this margin profile?
Lapiplasty Premium Defense
With the core Lapiplasty franchise ceding ground to your own MIS portfolio, how are you repositioning the upcoming product launches (like Lapiplasty Lightning) to defend premium price points and stop the top-line bleed?